

## Midsona

## Interim Report

## Quarter 2, 2023



2

## Summary of Q2 2023 and financial highlights

## Summary

- Net Sales negatively impacted by discontinued distribution agreements.
- Stable to good demand for our conventional brands. Challenges for organic products.
- Gross Profit \% strengthened considerably with support from price increases.
- Negative Fx effects.
- Improve EBITDA before one-offs.

Financial highlights

| Net sales | EBITDA ${ }^{1}$ | EBITDA ${ }^{1}$ margin |
| :---: | :---: | :---: |
| SEK 893 m <br> (SEK 956 m) | SEK 39 m <br> (SEK 34 m) | $\begin{gathered} 4,4 \% \\ (3,6 \%) \end{gathered}$ |
| -6,6\% change | +14,7\% | +0,8 p.p. |
| Gross margin ${ }^{1}$ | Net debt / Adj. EBITDA ${ }^{2}$ | Free cash flow |
| $\begin{gathered} 26,4 \% \\ (23,6 \%) \end{gathered}$ | $\begin{aligned} & 4,7 x \\ & (6,2) \end{aligned}$ | SEK 8 m <br> (SEK 53 m ) |
| +2,8. p.p. | Improved 1,5x | SEK -45m |



1) Before items affecting comparability. 2) EBITDA rolling 12-months, adjusted for transaction related costs

3

## Measures to turn around



[^0]
## Price management: Back to pre-war levels

## GM Gap Closing (vs YA)



## Pricing initiatives

- Price increases implemented in all markets during Q1 and Q2
- Gross margin clearly up vs PY, but still not at target levels
- New price increases are being considered


## Cost of goods

- Stabilization of raw materials prices.
- Fx
- EUR/SEK and USD/SEK negative effects
- EUR/NOK and USD/NOK negative effects


## Other cost

- Energy cost trending down


## Portfolio highlights

Organic productsHealthfoods
32\% gelnomax
SWEBAR ..... Criges
Consumer health products

- Growth -30\%
- Growth for own brands
- Decline completely related to discontinued licensed brands.


## Division Nordics



Net Sales EBITDA**

## Division North

|  | $\underline{23}$ | $\underline{22}$ | vs PY |
| :--- | :---: | :---: | :---: | :---: |
| Net Sales | 201 | 215 | $-7 \%$ |
| EBITDA*** $^{*}$ | 3 | 6 | $-50 \%$ |

- Net Sales decline solely explained by discontinued licensed brands
- Friggs is the shining star. Growth of $\mathbf{* 1 9 \%}$ in $\mathbf{q 2}$.
- Gross profit improvements but off target due to negative Fx effects
- Successful cost savings program
- Weak demand for organic products in the German market
- Minor gross profit improvements despite price increases. Negative mix effects. More private label and food service products.
- Focus on new volumes in the grocery trade and cost savings
- Net Sales growth comes from Private Label
- Certain production related issues remain in Spain

New cut-through concept for our organic brands Example: Kung Markatta
 HAR DI alltidekologiskt TÄNKT PÁBIEFFEKTERNA MED EKOLOGISKT?



Vibliver så rige, når dukøber vores varer.


Forward focus

## 1. Selective price increases

We see margin improvement in Q2, but we are still not back to 2021 levels. Accordingly, we will selectively increase prices in certain and maintain in other markets,

## 2. Volume focus

- Activate our brands with focus on high profit items
- Find new business opportunities for our core brands (listings, new customers)
- Private Label is booming. Leverage buoyed demand, but only at right margins.


## 3. EBITDA and Cash before Net Sales

- Further cost savings
- Complexity reduction project. Will discontinue nonperforming brands and products
- Continued inventory reduction over the year




## Financial review <br> CFO Max Bokander



## Financial Summary

| MSEK | Q2 2023 | Q2 2022 | YTD 2023 | YTD 2022 |
| :---: | :---: | :---: | :---: | :---: |
| Net Sales | 893 | 956 | 1867 | 1928 |
| GM\%* | 26,4 | 23,6 | 26,4 | 24,9 |
| EBITDA* | 39 | 34 | 99 | 96 |
| EBITDA\%* | 4,4 | 3,6 | 5,3 | 5,0 |
| IAC** | -14 | -6 | -19 | -6 |
| Net financing costs | -15 | -14 | -29 | -22 |
| Net tax costs | -2 | 7 | -10 | 5 |
| Net result | -32 | -20 | -38 | -8 |
| Free Cashflow | 8 | 53 | 84 | 38 |

## Comments QTD

- Net Sales - 6,6\%
- GM +2,8 p.p.
- EBITDA +5 M
- IAC; QTD restructuring cost 14 M linked to discontinuation of certain brands with mainly cost for write offs
- Net tax; higher than LY, due to good taxable results in some countries, but continued losses for some countries without activating these losses during the quarter.
* Before Items Affecting Comparability
** IAC including one off costs for impairment if applicable


## Q2 - Net sales

## midsona



## Q2 - EBITDA *

midsona


MSEK


[^1]
## Q2 - Sales, Marketing \& Admin Expenses*



* Before Items Affecting Comparability and excluding depreciation


## Q2 - Free Cash Flow

midsona


$\begin{array}{lllllllllllllll}\text { Q2 } & \text { Q3 } & \text { Q4 } & \text { Q1 } & \text { Q2 } & \text { Q3 } & \text { Q4 } & \text { Q1 } & \text { Q2 } & \text { Q3 } & \text { Q4 } & \text { Q1 } & \text { Q2 } & \text { Q3 } & \text { Q4 }\end{array}$ $\begin{array}{lllllllllllllllllllllllll}2019 & 2019 & 2019 & 2020 & 2020 & 2020 & 2020 & 2021 & 2021 & 2021 & 2021 & 2022 & 2022 & 2022 & 2022 & 2023 & 2023\end{array}$

* Before Items Affecting Comparability


## Available cash and Net Debt

midsona


Available Cash = Cash + available overdraft and unutilized contracted bank credit facilities


## Outlook 2023 Reaching higher

- Selective price increases going forward to offset negative Fx effects.
- Volume focus.
- Getting key brands back on the growth track
- Secure profitable Private Label contracts
- Continued cost savings
- Complexity reduction



[^0]:    Source: Company information

[^1]:    * Before Items Affecting Comparability

